Ruscogenin

DB15830InvestigationalSmall molecule

Ruscogenin is an anti-inflammatory steroid used in combination with local anesthetics for the treatment of hemorrhoids and for local anesthesia. A medication used to treat inflammation.

Mechanism: Pharmacologically active on Nuclear factor NF-kappa-B complex, NACHT, LRR and PYD domains-containing protein 3, and Thioredoxin-interacting protein
Curator reviewed
Formula / weight: C₂₇H₄₂O₄ · 430.629 g/mol (avg)

Resolves to

Compound

UNIIBXI92R2VUJCAS472-11-7ChEMBLCHEMBL1169820ChEBI8913KEGGD08498

Clinical / RWD

RxNorm35890

Structure

InChIKeyQMQIQBOGXYYATH-IDABPMKMSA-NSMILES

[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@@H](O)C[C@@H](O)[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2

Targets

Q96P20NLRP3Q9H3M7TXNIP

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

6Marketed productsAcross 3 countries and 4 labellers

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ruscogenin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account